Our success in treating ovarian cancer is increasing and advancing with the knowledge of the function of the immune system. Researchers are still challenged in exploring innate and adaptive immune systems. Ovarian cancer is the second most common type of gynecologic tumor in women worldwide and fifth leading cause of cancer death. Immunotherapy as a potentially promising approach for treatment of ovarian cancer is based on several lines of evidence. This therapy has been a promising development in the past few years.

It has several types based on the types of cells infected in the primary tumor, it could be either: 1-Epithelial cell 2-Germ Cell 3-Sex cord stromal cell. About 90 % of are Epithelial cells tumors, but despite this being the case, morphology classifies it into several more sub types such as serous, endometrioid, clear cell, and mucinous as well.

According to an estimate of American Cancer Society, United States in 2014, it was reported that about 21,980 new cases of ovarian cancer were diagnosed and 14,270 women get died. The rate of incidence is higher in women aged 55 to 64 years and median age of diagnosis is 63.

Although a lot of researches are done throughout the years by many foundations, still no exact cause is known. There are many predisposing factors related to its cause has been detected like: age, null gravidity, infertility, & advanced maternal age at first childbirth, women with endometriosis, cigarette smoking, obesity and dieting may affect its rate, family history of breast or ovarian cancer, early menarche or late menopause, and hormone therapy treatment may enhance possibility, also therapy including Hormone replacement.

It is well known that ovarian cancer is related to ovulation. There is growing evidence that estrogen, progesterone, and other hormones also play a role in the development and progression of ovarian cancer.

In addition to other conventional treatment, our expert team of medical oncologists and researchers are active and dynamic in the clinical trials related with various novel therapies including immunotherapy. Current immune based therapy for ovarian cancer fall into three broad categories: vaccines therapy, immune checkpoint inhibitors or blockers, , and adoptive T cell transfer therapy. The US Food and Drug Administration (FDA) approved drugs focusing on ovarian cancer include Bevacizumab which is a monoclonal antibody. Other drugs are currently under clinical trial for FDA approval which will help in saving lives of ovarian cancer patients.

The recent activities have increased our understanding of the tumor microenvironment, various immunotherapeutic modalities or combination therapy like chemotherapy with immunotherapy. In addition, the effects of such modalities in combination of immune based therapy on cancer patients are still investigative phase. In understanding the future of this therapy in treating cancer patients, proper preclinical and clinical designs are the important pillars. To extend the lives of ovarian cancer patients, immunotherapy’s that can induce or enhance optimal immunologic conditions within ovarian cancers may hold great promise.

contact us:160 Vista Oak Dr.

Longwood, FL 32779

Telephone:321-445-1969

Email id :info@gapsos.com

Web:http://www.gapsos.com/immuno-oncology.php